Horizon Discovery (LSE: HZD) is a world-leading gene editing company headquartered in the Cambridge, UK. Horizon’s platform comprises multiple precision gene editing technologies (our proprietary technology rAAV together with CRISPR and ZFN), and is underpinned by an extensive intellectual property estate of owned or in-licensed rights. Horizon participates in similar markets to life science tool and service stocks such as Abcam and Evotec, and uses gene editing to underpin the business similar to CRISPR stocks such as Editas and Intellia.